For your doctor to explain to you.
http://dgnews.docguide.com/blood-coagulation-detector-may-help-monitoring-stroke-risk?
An analyser recently developed to measure blood coagulability has
the sensitivity to detect hypercoagulatibility associated with stroke
risk in those without atrial fibrillation (AF), according to research
published in PLOS ONE.
To estimate the risk of stroke among patients with AF and determine
the requirement for anticoagulation therapy, the CHADS2 predictive score
is used. Because some parts of this score are also associated with
atherosclerosis risk and increased blood coagulability, a high score has
been proposed as linked to hypercoagulability in both patients with and
without AF. However, this association has not been fully investigated,
partly owing to the lack of a sensitive means of detection.
Researchers from the Tokyo Medical and Dental University (TMDU),
Tokyo, Japan, used a highly sensitive technique to measure small changes
in blood coagulation, and found hypercoagulability in patients without
AF with high CHADS2 scores.
Several physical and chemical factors affect blood clotting, some of
which can be measured over time to determine blood coagulability and the
likelihood of clot formation. Dielectric blood coagulometry (DBCM) is a
recently developed test that measures changes in the dielectric
permittivity of whole blood, representing clumping of red blood cells.
The researchers used DBCM to detect changes in the dielectric
permittivity of whole blood at 10 MHz. Comparisons between untreated
blood and that with added heparin or tissue factor enabled derivation of
a coagulability index.
“We calculated the end of acceleration time as an index of
coagulability from temporal changes in dielectric permittivity,” said
Satomi Hamada, TMDU. “This value reduced when tissue factor was added,
and increased with heparin present. It was also sensitive enough to
detect small changes in coagulability, particularly in
hypercoagulability.”
End of acceleration time (EAT) also boasts high reproducibility and
reliability. The researchers found that patients receiving warfarin had a
significantly longer EAT than those without, confirming the
anticoagulation effect. They also showed that patients with a high
CHADS2 score had a significantly shorter EAT that represented
hypercoagulability compared with patients with lower CHADS2 scores.
“"Intriguingly, EAT varied widely in patients with CHADS2 scores of 0
or 1,” said lead author Yuki Hasegawa, TMDU. “This suggests that DBCM
can identify high risk of thrombosis even in patients with low CHADS2
scores.”
SOURCE: Tokyo Medical and Dental University
No comments:
Post a Comment